Cyberknife, stereotactic body radiation therapy for hepatocellular carcinoma

Abstract

We evaluated local control of hepatocellular carcinoma (HCC) treated with Cyberknife, stereotactic body radiation therapy (SBRT). CyberKnife, SBRT system with real-time tumor tracking has good efficacy and low toxicity. 54 patients with 67 liver-confined HCC were treated with Cyberknife. Fiducials were implanted in the liver before treatment and were used as markers to track the lesion's movement. A total dose of 30 to 60 Gy in three fractions was prescribed to the 80% isodose line. Treatment response was evaluated by RECICL, CR: 82%, PR: 16%, PD: 2%. The local control rate was 92.3% at 1 year. Cyberknife was a safe, effective, noninvasive option for patients with HCC.